Tag Archives: reimbursement

Specialty Drugs and Reimbursement

By Ben Comer | Published: January 21, 2013
To maximize return on investment, pharma must think strategically about reimbursement channels and how new specialty products will perform in one versus another. By 2018, the amount health insurers spend per person on specialty, or biologic drugs, will equal or surpass the amount spent on traditional products, according to a new report. With the emergence [...]
Posted in Biotech, Strategy | Also tagged , , | Leave a comment

Ethics in Drug Innovation: The First Hurdle is Trust

By Guest Blogger | Published: October 19, 2012
By Ansis Helmanis Ethics is a matter of trust, which in the regulatory space requires transparency and openness among all stakeholders, including patients and industry.  This was the consensus of FDA Commissioner Margaret Hamburg and European Medicines Agency (EMA) Executive Director Guido Rasi, both of whom shared the podium with Nobel Laureate Professor Elie Wiesel [...]
Posted in Europe, Events, FDA, Global, Guest Blog, Market Access, Patient Communication, Regulatory, healthcare, leadership, pricing | Also tagged , , , , , , , | Leave a comment

EU Pins Hopes on HTA Network for Consensus on Value

By Guest Blogger | Published: August 29, 2012
The European Union’s proposed health technology assessment network to encourage “cooperation and exchange of scientific information among member states” is a significant step, says Reflector. But, as far as standardizing an approach to value is concerned, will it be a damp squib?
Posted in Europe, Global, Guest Blog, pricing | Also tagged , , , , , | Leave a comment

Prix Galien: Pharma R&D and Payers Need to Talk, Yesterday

By Ben Comer | Published: September 28, 2011
R&D departments and payers need to communicate early in the drug development process: If pharma is a day late, then payers are likely to be a dollar short, according to panelists at the Galien Forum on Tuesday.
Posted in FDA, Market Access, R&D, Strategy, leadership, pricing | Also tagged , , , | Leave a comment

Value Isn't Just Dollars and Cents, says Pfizer Exec

By Ben Comer | Published: September 23, 2011
Now that 90% of the top 43 countries for drug sales have instituted “significant” cost containment measures, it’s more important than ever to give payers the rest of the story, according to a Pfizer executive.
Posted in Europe, Global, Market Access, Marketing, Patient Communication, Strategy, healthcare, pricing | Tagged | Leave a comment